CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the use of mirabegron, a drug that activates specific receptors in the heart, to treat patients at risk of heart failure. It aims to assess its effectiveness in reducing heart muscle thickening and improving heart function in individuals with structural heart disease.
Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population.
There is currently no specific, defined treatment for HFpEF, beyond control of risk factors.
Activation of cardiac and vascular Beta3-adrenergic receptors (B3AR) represents a new concept and a novel target for structural cardiac disease. B3AR expression and coupling were demon…
UNIVERSITE CATHOLIQUE DE LOUVAIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
CLINIQUES UNIVERSITAIRES SAINT-LUC ASBL
Belgium, Bruxelles / Brussel
Type: Other
Activity type: Other
SME: No
Poland, Wroclaw
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Portugal, Lisboa
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Portugal, Lisbon
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
